In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: St. Jude Medical

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical: "Dutch auction" self-tender offer commences Feb. 12 for the repurchase of up to 8 mil. shares of stock. Under the terms of the offer, shareholders have an opportunity to specify prices between $32 and $39 per share at which they are willing to tender their shares. Upon receipt of the tenders, St. Jude will offer a price at or below the requested purchase prices that will enable it to purchase up to 8 mil. shares. The issue closed at $34.6875 on Feb. 11. Approximately 91.9 mil. shares are outstanding. Commenting on the offer that expires March 12, St. Jude Chairman and CEO Ronald Matricaria says: "The board of directors believes this offer is an attractive use of the company's financial resources and that the use of cash and borrowing to fund the offer will result in a more efficient capital structure for St. Jude." Credit Suisse First Boston is dealer manager for the offer...
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel